Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy (CART19-BE-01)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03144583 |
Recruitment Status :
Completed
First Posted : May 9, 2017
Last Update Posted : August 28, 2023
|
Sponsor:
Sara V. Latorre
Collaborator:
Instituto de Salud Carlos III
Information provided by (Responsible Party):
Sara V. Latorre, Institut d'Investigacions Biomèdiques August Pi i Sunyer
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | April 26, 2017 | ||||
First Posted Date ICMJE | May 9, 2017 | ||||
Last Update Posted Date | August 28, 2023 | ||||
Actual Study Start Date ICMJE | June 15, 2017 | ||||
Actual Primary Completion Date | September 13, 2022 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy | ||||
Official Title ICMJE | Pilot Study on the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity Conjugated With the Co-stimulatory Regions 4-1BB and CD3z in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy | ||||
Brief Summary | To assess the infusion of ARI-0001 cells (Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity [A3B1] conjugated with the co-stimulatory regions 4-1BB and CD3z ) safety on patients with leukemia or lymphoma CD19+ resistant or refractory to treatment and with a prognosis of less than 2 years. | ||||
Detailed Description | Not Provided | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 | ||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Masking Description: Open label Primary Purpose: Other
|
||||
Condition ICMJE |
|
||||
Intervention ICMJE | Biological: Adult differentiated autologous T-cells
After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
|
||||
Study Arms ICMJE | Experimental: Adult differentiated autologous T-cells
Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z. Such cells will be administered in a single infusion intravenously at a total ARI-0001 cell dose of 0.5-10 x 106 / kg body weight.
Intervention: Biological: Adult differentiated autologous T-cells
|
||||
Publications * |
|
||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Actual Enrollment ICMJE |
50 | ||||
Original Estimated Enrollment ICMJE |
10 | ||||
Actual Study Completion Date ICMJE | September 13, 2022 | ||||
Actual Primary Completion Date | September 13, 2022 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 2 Years to 80 Years (Child, Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | Spain | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03144583 | ||||
Other Study ID Numbers ICMJE | CART19-BE-01 | ||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Current Responsible Party | Sara V. Latorre, Institut d'Investigacions Biomèdiques August Pi i Sunyer | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor ICMJE | Sara V. Latorre | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE | Instituto de Salud Carlos III | ||||
Investigators ICMJE |
|
||||
PRS Account | Institut d'Investigacions Biomèdiques August Pi i Sunyer | ||||
Verification Date | August 2023 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |